U.S. markets open in 2 hours 2 minutes
  • S&P Futures

    4,511.25
    0.00 (0.00%)
     
  • Dow Futures

    35,317.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    15,410.75
    +12.25 (+0.08%)
     
  • Russell 2000 Futures

    2,268.80
    -4.00 (-0.18%)
     
  • Crude Oil

    82.03
    -0.93 (-1.12%)
     
  • Gold

    1,781.90
    +11.40 (+0.64%)
     
  • Silver

    23.99
    +0.11 (+0.45%)
     
  • EUR/USD

    1.1632
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.6350
    0.0000 (0.00%)
     
  • Vix

    15.64
    -0.67 (-4.11%)
     
  • GBP/USD

    1.3753
    -0.0040 (-0.29%)
     
  • USD/JPY

    114.4100
    +0.0500 (+0.04%)
     
  • BTC-USD

    63,805.49
    +1,628.83 (+2.62%)
     
  • CMC Crypto 200

    1,480.68
    +17.33 (+1.18%)
     
  • FTSE 100

    7,221.31
    +3.78 (+0.05%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

What's Going On With Corvus Pharmaceuticals Stock Today?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC (NASDAQ: AZN) for patients with unresectable, stage 3 non-small cell lung cancer.

The average session volume over a 100-day period is about 300,000. Friday's session volume was approaching 120 million at publication time.

AZN News: AstraZeneca announced that "the COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival and objective response rate compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer who had not progressed after concurrent chemoradiation therapy."

The results may be positively impacting Corvus Pharmaceuticals, which has a CD73 asset in its pipeline.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system.

CRVS Price Action: Corvus Pharmaceuticals has traded as high as $5.74 and as low as $1.86 over a 52-week period.

The stock was up 72.60% at $3.90 at time of publication.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.